INDEPENDENT THINKING. BETTER EVIDENCE.WEIGHT, HEALTH & THE SCIENCE BETWEEN
WEIGHT-LOSS DRUG TRACKER

Survodutide

Survodutide is an investigational GLP-1 and glucagon receptor agonist. Its obesity and liver-disease research programs ask different clinical questions.

Single conceptual survodutide carton labeled Illustration and Investigational.
Conceptual SURVODUTIDE carton for this medicine profile, not a photograph of commercial packaging or clinical-trial supplies. The drug is investigational; this image does not establish regulatory approval.

Survodutide is an investigational GLP-1 and glucagon receptor agonist. Its obesity and liver-disease research programs ask different clinical questions.

SYNCHRONIZE-1 studied people without diabetes. SYNCHRONIZE-2, published on 1 October 2026, studied adults with obesity and type 2 diabetes over 76 weeks. Treatment-regimen and efficacy-estimand figures should not be silently interchanged.

A separate MASH program evaluates a specific liver disease and fibrosis-related outcomes. Reduced liver fat, improved fibrosis, and prevention of later clinical events are not interchangeable claims.

Trial route and frequency describe research protocols only. No approved brand, dose, or routine-care availability has been verified here. Products marketed using the molecule’s name cannot be assumed equivalent to the study product.

Regulatory status checked on 3 October 2026

United States: FDA approval has not been verified. An FDA warning letter dated 24 August 2026 identifies marketed survodutide products as unapproved. October Phase 3 publication is not approval evidence.

European Union: EU marketing authorisation has not been verified in this review. No approved EU product is asserted.

Official records and primary evidence

Route and frequency describe approved product records or clinical-trial protocols as identified above. They are not instructions to use, obtain, combine, or dose a medicine. This record is informational and has not been independently medically reviewed.

Official references

  1. FDA warning concerning unapproved peptides ↗
  2. SYNCHRONIZE-1 Phase 3 paper ↗
  3. SYNCHRONIZE-2 Phase 3 paper ↗
  4. Survodutide October 2026 update ↗
  5. Survodutide MASH Phase 3 registry summary ↗

Clinical trial evidence

Registry status and published results are shown separately. Treatment averages across different studies are not a ranking or a prediction for an individual.

SYNCHRONIZE-1

NCT06066515 · Survodutide profile

Sponsor
Boehringer Ingelheim
Phase
Phase 3
Registry status
completed
Registry enrollment
726 (actual)
Published analysis population
725
Analysis time point
76 weeks
Population
Adults with obesity, or overweight with weight-related complications, without diabetes. Exact eligibility differs by trial; consult the linked protocol.
Registry checked
2026-10-03

Registry actual enrollment is 726; the paper abstract reports outcomes among 725 participants. This dataset retains both denominators without assuming why they differ.

Published mean body-weight change at 76 weeks · treatment-regimen
Historical trial armMean change from baseline
survodutide up to 3.6 mg trial arm-12.2%
survodutide up to 6.0 mg trial arm-13.0%
placebo-5.4%

Negative values indicate a decrease from baseline. Arm dose labels describe the research protocol, not a dosing recommendation.

Original study abstract · Full registry record

The original abstract and registry were checked; full texts and supplements were not independently reviewed. Confidence intervals absent from this record must not be inferred. These selected results do not describe every safety finding or subgroup.

Evidence, explainers and reporting

The medicine profile is a reference point. These articles address narrower questions and developments.

← Back to the drug tracker
Cookie policy